$1.1 B

NTLA Mkt cap, 14-Jun-2018
Intellia Therapeutics Net income (Q1, 2018)-21.4 M
Intellia Therapeutics EBIT (Q1, 2018)-22.4 M
Intellia Therapeutics Cash, 31-Mar-2018327.8 M

Intellia Therapeutics Financials

Intellia Therapeutics Income Statement

Annual

USDFY, 2016

R&D expense

11.3 b

General and administrative expense

5.1 b

Operating expense total

16.4 b

EBIT

(10.8 b)

Interest income

259 m

Pre tax profit

(10.6 b)

Net Income

(10.6 b)

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

R&D expense

5.2 m7.4 b7.9 b13.4 m15.6 m22.5 m

General and administrative expense

3.2 m3.7 b4.7 b5.7 m6.4 m7.4 m

Operating expense total

8.5 m11.2 b12.6 b19.2 m21.9 m29.9 m

EBIT

(6.7 m)(6.9 b)(7.7 b)(12.9 m)(16 m)(22.4 m)

Interest income

5 k46 m215 m317 k424 k1.1 m

Pre tax profit

(6.7 m)(6.9 b)(7.5 b)

Income tax expense

Net Income

(6.7 m)(6.9 b)(7.5 b)(12.6 m)(15.6 m)(21.4 m)

Intellia Therapeutics Balance Sheet

Annual

USDFY, 2016

Cash

273.1 m

Accounts Receivable

6.5 m

Inventories

1.8 m

Current Assets

281.3 m

PP&E

10.6 m

Total Assets

299 m

Accounts Payable

4.7 m

Current Liabilities

30.7 m

Additional Paid-in Capital

263.4 m

Retained Earnings

(53.6 m)

Total Equity

209.8 m

Financial Leverage

1.4 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

64.2 m300.7 m290.6 m257.6 m241 m327.8 m

Accounts Receivable

1 m1 m1.1 m2.4 m2.8 m7.5 m

Current Assets

65.9 m302.9 m292.7 m261.1 m245.9 m337.7 m

PP&E

4.2 m4.4 m5.5 m11.4 m12.6 m16 m

Total Assets

75.5 m310.6 m301.5 m279.3 m265 m359.5 m

Accounts Payable

1.2 m1 m657 k1.4 m2.3 m1.9 m

Current Liabilities

11 m21.6 m22.6 m24.9 m26.4 m25.6 m

Additional Paid-in Capital

1.5 m259.1 m261.1 m266.1 m269.4 m432.5 m

Retained Earnings

(28.6 m)(35.5 m)(43 m)(66.2 m)(81.8 m)(137 m)

Total Equity

(27.1 m)223.6 m218.1 m199.9 m187.6 m295.5 m

Financial Leverage

-2.8 x1.4 x1.4 x1.4 x1.4 x1.2 x

Intellia Therapeutics Cash Flow

Annual

USDFY, 2016

Net Income

(10.6 b)

Depreciation and Amortization

3 k

Accounts Receivable

(5.5 m)

Inventories

(285 k)

Accounts Payable

163 k

Cash From Operating Activities

(2.3 m)

Purchases of PP&E

(275 k)

Cash From Investing Activities

(575 k)

Cash From Financing Activities

12.7 m

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(6.7 m)(13.6 m)(21.1 m)(12.6 m)(28.2 m)(21.4 m)

Depreciation and Amortization

187 k434 k699 k660 k1.4 m1 m

Accounts Receivable

(112 k)4 m3.7 m3 m

Accounts Payable

(87 k)(367 k)154 k(954 k)(670 k)59 k

Cash From Operating Activities

(9.4 m)58.1 m50.5 m(11.4 m)(27.1 m)(17.8 m)

Purchases of PP&E

(1 m)(2.2 m)(2.8 m)(4.2 m)(5.4 m)(1.9 m)

Cash From Investing Activities

(1 m)(2.2 m)(2.8 m)(4.2 m)(5.4 m)(1.9 m)

Cash From Financing Activities

(1.2 m)168.9 m167 m47 k493 k6.7 m

Intellia Therapeutics Ratios

USDY, 2018

Financial Leverage

1.2 x
Report incorrect company information